Our clinical plan for GALGT2 gene therapy has been to move from intramuscular (IM) injection to isolated limb infusion (ILI) studies, and finally to systemic intravenous (IV) delivery in DMD patients. The gene discussed is B4GALNT2; the disease is Duchenne muscular dystrophy.